Adial Pharmaceuticals (ADIL) Other Accumulated Expenses (2018 - 2026)
Adial Pharmaceuticals (ADIL) posted Other Accumulated Expenses of $10000.0 for Q1 2026, down 87.1% sequentially from $77495.0 in Q4 2025, and down 90.84% YoY from $109145.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Other Accumulated Expenses for 8 years, with the latest figure at $10000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 90.84% year-over-year to $10000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10000.0 (down 90.84% YoY) and the FY2025 annual result came in at $77495.0, changed N/A from the prior year.
- Other Accumulated Expenses fell to $10000.0 in Q1 2026 per ADIL's latest filing, from $77495.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $813371.0 in Q3 2023 and troughed at $3638.0 in Q1 2023.
- A 5-year average of $80756.3 and a median of $10387.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 9599.15% in 2023, then sank 99.28% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $10387.0 in 2022, then jumped by 361.56% to $47942.0 in 2023, then tumbled by 87.87% to $5816.0 in 2024, then surged by 1232.44% to $77495.0 in 2025, then sank by 87.1% to $10000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $10000.0, $77495.0, and $45996.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 77,495.00 |
| Sep 30, 2025 | 45,996.00 |
| Jun 30, 2025 | 45,994.00 |
| Mar 31, 2025 | 109,145.00 |
| Sep 30, 2024 | 5,816.00 |
| Jun 30, 2024 | 5,816.00 |
| Dec 31, 2023 | 47,942.00 |
| Sep 30, 2023 | 813,371.00 |
| Jun 30, 2023 | 5,639.00 |
| Mar 31, 2023 | 3,638.00 |
| Dec 31, 2022 | 10,387.00 |
| Sep 30, 2022 | 8,386.00 |
| Jun 30, 2022 | 11,860.00 |
| Mar 31, 2022 | 9,859.00 |
| Dec 31, 2021 | 9,683.00 |
| Sep 30, 2021 | 30,000.00 |
| Jun 30, 2021 | 20,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 40,000.00 |